Last updated: October 31, 2026
BioThrax, Emergent BioSolutions’ anthrax vaccine adsorbed, is a government-procurement product rather than a conventional commercial biologic. Its market is controlled by U.S. national-security purchasing, stockpile replenishment, manufacturing capacity, and federal contract timing. Emergent does not report BioThrax revenue as a standalone product line, so product-level revenue, margin, and valuation cannot be calculated directly from public filings. The commercial outlook is stable but concentrated, with limited private-market demand and high dependence on U.S. government contracts.
What is BioThrax and who manufactures it?
BioThrax is an anthrax vaccine adsorbed indicated for active immunization against disease caused by Bacillus anthracis in adults and certain pediatric populations. Emergent BioSolutions manufactures and markets the product in the United States under FDA biologics license application No. 103795. The vaccine is administered through a multi-dose primary series followed by boosters for individuals at continuing risk of exposure. (FDA, 2023a)
| Item |
BioThrax position |
| Product |
BioThrax, anthrax vaccine adsorbed |
| Manufacturer |
Emergent BioSolutions Inc. |
| Regulatory category |
FDA-licensed vaccine biologic |
| FDA license |
BLA 103795 |
| Primary buyers |
U.S. government agencies and contractors |
| Principal end market |
Strategic National Stockpile and military procurement |
| Main competitor |
CYFENDUS, formerly AV7909 |
| Commercial market |
Limited civilian demand |
| Biosimilar exposure |
Low |
| Reimbursement exposure |
Low |
| Revenue disclosure |
Included in broader product or government-contract reporting |
The U.S. government has used BioThrax as a core anthrax stockpile product for the Strategic National Stockpile and Department of Defense programs. The government’s purchasing decision is based on readiness, shelf life, delivery schedules, regulatory status, manufacturing continuity, and the need to maintain multiple approved countermeasures.
How does BioThrax make money?
BioThrax generates revenue primarily through government contracts, not routine pharmacy, hospital, or physician sales. The U.S. government purchases vaccine doses for stockpiling, military use, and preparedness programs. This produces a procurement-driven revenue model with large contract awards and irregular shipment schedules.
The main economic characteristics are:
- Revenue is lumpy because large government orders can be recognized over specific delivery periods.
- Pricing is negotiated through federal procurement rather than ordinary commercial competition.
- Demand is tied to inventory replacement, expiration management, preparedness policy, and new stockpile requirements.
- The customer base is highly concentrated.
- Private-sector demand is too limited to offset a major federal purchasing interruption.
Emergent reports government services and product revenue across broader business categories. Public filings do not consistently disclose BioThrax sales separately from other medical-countermeasure products. As a result, analysts should not treat Emergent’s total government-services revenue as BioThrax revenue.
What is the financial trajectory for BioThrax?
BioThrax’s financial trajectory is best described as contract-dependent and strategically important, rather than as a steadily growing branded pharmaceutical franchise.
Revenue trajectory
The principal drivers are:
- Federal stockpile replenishment.
- Orders from the Department of Defense.
- Dose expiration and replacement cycles.
- New or expanded anthrax preparedness programs.
- Production capacity and batch release timing.
- Contract modifications, options, and delivery schedules.
BioThrax revenue can rise sharply when a major federal procurement is awarded or delivered. It can decline in periods when the government has sufficient inventory or shifts purchases toward another anthrax vaccine. Product revenue therefore does not track population prevalence or ordinary vaccine uptake.
Emergent’s broader financial results have also been affected by restructuring, debt obligations, facility costs, contract timing, and performance across other medical-countermeasure products. BioThrax should be valued as a strategic government asset, but its contribution to consolidated results must be separated from the company’s other products before estimating product-level economics. (Emergent BioSolutions, 2024)
Margin and cash-flow considerations
BioThrax has characteristics that can support attractive contribution margins after a validated manufacturing process is established:
- The product is established and FDA licensed.
- The buyer is concentrated and procurement is often planned.
- Sales and marketing costs are lower than for primary-care biologics.
- The product has strategic value that can support long-term government relationships.
The main cost risks are different from those affecting commercial vaccines. They include:
- Maintaining specialized manufacturing infrastructure.
- Compliance with current good manufacturing practice requirements.
- Lot testing and release delays.
- Inventory carrying costs.
- Capacity reservations.
- Facility remediation or quality-system upgrades.
- Small-volume manufacturing economics outside government orders.
A sharp loss of a federal contract could reduce utilization and raise per-dose manufacturing costs. Contract renewal does not guarantee stable annual revenue because the government can alter quantities, delivery windows, or product mix.
What government agencies buy BioThrax?
The major purchasing channels are the U.S. Strategic National Stockpile and military-related procurement programs. The Biomedical Advanced Research and Development Authority and the Administration for Strategic Preparedness and Response can also influence countermeasure development and acquisition, although agency involvement varies by contract.
The government’s anthrax procurement strategy generally seeks:
- Adequate stockpile volume.
- Products with FDA approval or licensure.
- Shelf-life extensions where scientifically and regulatorily supportable.
- Multiple suppliers or products to reduce single-source risk.
- Rapid deployment capability.
- Manufacturing continuity during a public-health emergency.
Because anthrax is a national-security threat, the purchase decision is not based solely on ordinary cost-per-dose comparisons. Regulatory status, supply assurance, and readiness have material commercial value.
How does BioThrax compare with CYFENDUS?
CYFENDUS, formerly AV7909, is Emergent’s newer anthrax vaccine product and is designed to require a two-dose primary series rather than the longer BioThrax primary schedule. The FDA approved CYFENDUS in 2023 for adults 18 to 65 years of age for post-exposure prophylaxis, in conjunction with recommended antibacterial drugs. (FDA, 2023b)
| Factor |
BioThrax |
CYFENDUS |
| Product type |
Anthrax vaccine adsorbed |
Anthrax vaccine adsorbed with CpG 7909 adjuvant |
| Manufacturer |
Emergent |
Emergent |
| FDA status |
Licensed |
Licensed |
| Primary commercial role |
Established stockpile and military product |
Newer post-exposure countermeasure |
| Dosing profile |
Longer primary series |
Two-dose primary series for approved use |
| Strategic value |
Existing supply and regulatory history |
Faster post-exposure immunization profile |
| Cannibalization risk |
Possible over time |
Potentially replaces some future BioThrax demand |
| Government relevance |
High |
High |
CYFENDUS creates both a competitive advantage and a portfolio risk for Emergent. The company can capture more government spending through a broader anthrax portfolio, but government adoption of CYFENDUS could reduce future demand for some BioThrax orders. The extent of substitution depends on the government’s use case, inventory strategy, cost, available supply, and deployment requirements.
When does BioThrax lose exclusivity?
BioThrax does not have a single commercially decisive small-molecule patent-expiration date. It is a vaccine biologic whose market protection depends on FDA licensure, manufacturing capability, regulatory compliance, procurement relationships, know-how, and government qualification.
Publicly available regulatory materials do not establish a single foundational BioThrax patent that determines market entry in the manner of a conventional small-molecule drug. Analysts should distinguish:
- Patent expiry.
- Biologics license competition.
- Government procurement eligibility.
- Manufacturing comparability.
- Facility and lot-release requirements.
- Contractual supply qualification.
A competitor could face substantial operational barriers even after relevant patents expire. Conversely, patent protection alone would not prevent competition if the competitor obtains a separate licensed anthrax vaccine and qualifies for federal procurement.
What is the Orange Book status of BioThrax?
BioThrax is regulated as a biologic vaccine under an FDA biologics license application rather than as a conventional New Drug Application product. The Orange Book is therefore not the principal source for assessing its competitive protection.
The more relevant regulatory sources are:
- FDA biologics license records.
- FDA product labeling.
- Vaccine approval and supplement history.
- Federal acquisition records.
- Strategic National Stockpile procurement announcements.
- Emergent annual reports and contract disclosures.
BioThrax also is not a conventional biosimilar-risk product. The U.S. biosimilar pathway under the Public Health Service Act is not the normal competitive route for an anthrax vaccine of this type. A competing product would generally require its own regulatory authorization or a different applicable FDA pathway.
What patent and manufacturing barriers protect BioThrax?
BioThrax’s strongest barriers are operational rather than purely patent-based.
Manufacturing barriers
The principal barriers include:
- Validated production processes.
- Specialized antigen production.
- Adjuvant and formulation controls.
- Sterility and potency testing.
- Consistent lot manufacture.
- Regulatory inspection readiness.
- Long-term product stability data.
- Federal qualification and delivery performance.
Anthrax vaccine manufacturing requires more than reproducing a published formulation. A competitor must demonstrate product quality, clinical or regulatory acceptability, manufacturing consistency, and reliable supply.
Intellectual-property barriers
Potential IP protection may cover manufacturing methods, formulations, adjuvants, dosing regimens, analytical methods, and improvements to next-generation products. However, the commercial importance of any individual patent depends on claim scope, remaining term, validity, and whether a competing anthrax vaccine can design around the claims.
The most relevant IP risk for BioThrax is portfolio substitution by CYFENDUS or another countermeasure, not ordinary generic entry.
Which companies are challenging BioThrax?
No conventional generic company has emerged as a major BioThrax challenger in the U.S. market. The principal competitive threat is product substitution by other licensed anthrax vaccines, especially CYFENDUS, rather than a Paragraph IV challenge.
The competitive landscape includes:
| Competitor or alternative |
Competitive relevance |
| CYFENDUS |
Most direct U.S. portfolio competitor |
| ACAM2000 |
Smallpox vaccine, not a BioThrax substitute |
| Other national anthrax vaccines |
Potential international or government alternatives |
| Unlicensed candidates |
Future preparedness competition |
| Generic manufacturers |
Low near-term relevance |
Are there Paragraph IV challenges or BioThrax patent lawsuits?
BioThrax is not a typical target for Paragraph IV litigation because it is not marketed through the standard small-molecule ANDA framework. Publicly available information does not identify a major active U.S. Paragraph IV campaign against BioThrax.
The more likely legal disputes involve:
- Government contract performance.
- Procurement protests.
- Manufacturing compliance.
- Product liability.
- Patent claims concerning vaccine improvements or production methods.
- Contract termination or modification.
- Disputes involving successor anthrax products.
No major publicly reported patent settlement comparable to those common in branded small-molecule pharmaceuticals defines the BioThrax market.
What FDA milestones affect BioThrax?
| Year |
Milestone |
| 2002 |
FDA approval of BioThrax for pre-exposure prophylaxis in adults at occupational risk |
| 2008 |
FDA expanded the indication to include post-exposure prophylaxis with appropriate antibacterial therapy |
| 2012 |
FDA approval expanded use to pediatric patients in specified age groups |
| 2023 |
FDA approved CYFENDUS for post-exposure prophylaxis in adults 18 to 65 |
The approval of CYFENDUS changed Emergent’s anthrax product strategy. BioThrax remains an established product, but future government demand may be allocated across products according to dosing, deployment, inventory, and procurement priorities.
What generic launch risks exist for BioThrax?
A conventional generic launch risk is low. The material risks are government-market and portfolio risks:
- CYFENDUS captures new anthrax procurement.
- Federal stockpile inventories reduce near-term replacement orders.
- Government buyers diversify supply.
- Contract renewals are delayed or awarded at lower volumes.
- Manufacturing interruptions reduce available supply.
- A competing licensed vaccine gains procurement preference.
- Emergent’s financial constraints affect production investment or delivery performance.
The highest-probability downside is not a sudden generic launch. It is a gradual reduction in BioThrax order volume as procurement shifts toward newer products or as stockpile requirements change.
What is the licensing and commercial outlook?
BioThrax’s commercial value is tied to Emergent’s federal contracting position and manufacturing infrastructure. Licensing opportunities are more likely to involve:
- Regional distribution.
- Government supply agreements.
- International preparedness programs.
- Manufacturing or fill-finish arrangements.
- Technology transfer.
- Portfolio transactions involving anthrax or other medical countermeasures.
Traditional commercial licensing economics are limited because civilian demand is small and government procurement often requires direct supplier qualification. Emergent’s stronger negotiating asset is the ability to provide a regulated, established anthrax vaccine and related countermeasure capacity.
How strong is the BioThrax market position?
BioThrax has a strong regulatory and procurement position but a concentrated commercial profile.
| Risk category |
Assessment |
| Regulatory barrier |
High |
| Manufacturing barrier |
High |
| Patent exclusivity |
Product-specific and less decisive than manufacturing |
| Biosimilar threat |
Low |
| Generic threat |
Low |
| Government concentration |
Very high |
| Portfolio substitution risk |
Moderate to high |
| Civilian demand |
Low |
| Revenue predictability |
Moderate to low |
| Strategic value |
High |
| Standalone financial transparency |
Low |
Key Takeaways
- BioThrax is a government-procurement vaccine, not a conventional retail biologic.
- Emergent does not disclose BioThrax revenue as a standalone financial line.
- Revenue depends on stockpile purchases, military demand, replacement cycles, and federal contract timing.
- CYFENDUS is the most important competitive and substitution risk.
- Paragraph IV litigation and ordinary generic entry are not the principal threats.
- Manufacturing capability, regulatory compliance, supply reliability, and federal qualification provide the strongest practical barriers.
- BioThrax’s financial trajectory should be modeled through government-contract awards and deliveries rather than market-share assumptions.
- The product has strategic value, but its concentrated customer base limits revenue visibility.
FAQs
Is BioThrax still FDA approved?
Yes. BioThrax remains an FDA-licensed anthrax vaccine under BLA 103795, subject to its approved labeling and post-approval requirements.
Does BioThrax have biosimilar competition?
No major biosimilar competitor is publicly established in the U.S. market. A competing anthrax vaccine would generally require its own regulatory authorization.
Is BioThrax sold directly to consumers?
No. Its principal market is government procurement for stockpiles, military programs, and preparedness activities.
Can CYFENDUS replace BioThrax?
CYFENDUS can compete for some future anthrax procurement, particularly where a two-dose post-exposure regimen has operational value. It does not automatically eliminate BioThrax demand across all government use cases.
What is the main investment risk tied to BioThrax?
The main risk is federal procurement concentration. Revenue can decline if the government reduces orders, delays replenishment, shifts purchases to CYFENDUS, or changes its anthrax preparedness strategy.
References
-
Emergent BioSolutions Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2023. U.S. Securities and Exchange Commission.
-
U.S. Food and Drug Administration. (2023a). BioThrax anthrax vaccine adsorbed: Prescribing information. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2023b). FDA approves CYFENDUS anthrax vaccine for post-exposure prophylaxis. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. U.S. Department of Health and Human Services.
-
U.S. Department of Health and Human Services. (2024). Strategic National Stockpile and medical countermeasure procurement materials. Administration for Strategic Preparedness and Response.
